<DOC>
	<DOCNO>NCT00002623</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether chemotherapy follow surgery without radiation therapy effective chemotherapy follow radiation therapy alone treat non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy follow surgery without radiation therapy chemotherapy follow radiation therapy alone treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Surgery Radiation Therapy Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient stage IIIA non-small cell lung cancer treat surgery without radiotherapy versus radiotherapy alone achieve response neoadjuvant chemotherapy regimen contain cisplatin carboplatin . - Compare progression-free survival patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , response induction chemotherapy ( complete vs partial v minor ) , histological subtype ( squamous vs nonsquamous ) . All patient receive 3 course induction combination chemotherapy comprise cisplatin carboplatin absence disease progression unacceptable toxicity . Patients complete partial response ( minor response disease become resectable ) randomize 1 2 treatment arm . - Arm I : Within 6 week randomization , patient undergo radical lobectomy pneumonectomy plus dissection hilar mediastinal lymph node . Patients positive resection margin least 1 cm and/or positive mediastinal node undergo radiotherapy 5 day week 5.5 week . Patients postresection subclinical/microscopic disease negative tumor margin undergo radiotherapy 5 day week 4-4.5 week . - Arm II : Within 6 week randomization , patient undergo primary radiotherapy . Patients subclinical/microscopic disease negative tumor margin undergo radiotherapy 5 day week 4-4.5 week . Patients gross tumor volume tumor margin least 1 cm undergo radiotherapy 5 day week 6 week . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 640 patient accrue study within 8 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven primary unresectable nonsmall cell lung cancer ( NSCLC ) mediastinoscopy , mediastinotomy , thoracotomy , videoassisted thoracic surgery , needle biopsy Stage IIIA ( N2 ) disease chest CT scan Any histologic subtype allow At least 1 unidimensionally bidimensionally measurable target lesion chest CT scan No N3 metastatic disease physical exam , CT scan thorax , bone scan , CT scan ultrasound liver adrenals No preexist pleural pericardial effusion No symptomatic CNS involvement PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No superior vena cava syndrome Pulmonary : No diffuse interstitial pulmonary fibrosis Other : No prior melanoma , breast cancer , hypernephroma No primary malignancy within past 5 year except adequately treat basal cell skin cancer carcinoma situ cervix No grade 2 great preexist motor sensory neurotoxicity No active uncontrolled infection require IV antibiotic Must physically mentally fit study therapy No psychological , familial , sociological , geographical condition would preclude study compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy NSCLC Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy NSCLC Surgery : No prior surgery NSCLC Other : No prior therapy NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>